

Contents

Contributors list	vii
Editor biography	ix
1 Introduction and disease overview	1
References	9
2 Incretin hormones as a target for therapy	11
Incretin hormone physiology	11
The incretin-producing cell	11
GIP and GLP-1 action	13
Measurement of the incretin hormones	17
Incretin action in healthy individuals	18
Incretin action in patients with type 2 diabetes	18
Therapeutics application	21
References	26
3 Glucagon-like peptide receptor agonists	31
Introduction	31
GLP-1 receptor agonists	32
Extrapankreatic effects GLP-1 receptor agonists	37
Pancreatic safety	39
Perspectives	40
References	41
4 Dipeptidyl peptidase-4 inhibitors	45
Introduction	45
Pharmacokinetics and pharmacodynamics	45
Efficacy	47
Combination therapy	48
Use in specific patient populations	50
Safety	52

Conclusions	57
References	58
5 Global position and recommendations for use	61
Introduction	61
American Association of Clinical Endocrinologists/American College of Endocrinology	61
American Diabetes Association /European Association for the Study of Diabetes	65
International Diabetes Federation	65
National Institute of Health and Care Excellence	67
Using incretin-based therapies in clinical practice	70
Availability and licences	71
References	74
6 Future and emerging therapies	77
Introduction	77
Once-weekly agents under investigation	77
Subcutaneous implants	81
Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors	84
Other indications for incretin therapies	85
DPP-4 inhibitors	86
References	89

Handbook of Incretin-based Therapies in Type 2
Diabetes

Gough, S. (Ed.)

2016, IX, 92 p. 20 illus., 16 illus. in color., Softcover

ISBN: 978-3-319-08981-2